Date Closed

June 12, 2023

Lead Office

Québec City

Value

16.50 Million CAD

On June 12, 2023, Feldan Bio Inc. ("Feldan") completed a C$16.5 million Series B investment round that will see new investors Investissement Québec, Amgen Ventures (United States), GC Cell (South Korea) and FSIT2 join the renewed support of GC Holdings (South Korea) and other existing shareholders. The funding will help Feldan bring breakthrough treatments for basal cell carcinomas, the most common skin cancer and most frequent form of all cancers, to clinical development.

Feldan, based in Québec City, Québec, is a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics. Feldan's pipeline focuses on diseases affecting skin and lungs.

Investissement Québec's mission is to play an active role in Québec's economic development by stimulating business innovation, entrepreneurship and business acquisitions, as well as growth in investment and exports.

McCarthy Tétrault advised Feldan with a team led by Charles-Antoine Soulière that included Alexandre Saulnier-Marceau, Philippe April, Kim Godbout (Business), Marie-Soleil Landry, Geneviève Favreau (Tax), David Paradis, and Nadine Houle (Labour & Employment).